预约演示
更新于：2026-03-14
Travoprost/Timolol Maleate
曲伏噻吗
更新于：2026-03-14
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS号874755-80-3 |
关联
38
项与 曲伏噻吗 相关的临床试验NCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 项与 曲伏噻吗 相关的临床结果
登录后查看更多信息
100 项与 曲伏噻吗 相关的转化医学
登录后查看更多信息
100 项与 曲伏噻吗 相关的专利（医药）
登录后查看更多信息
79
项与 曲伏噻吗 相关的文献（医药）2026-02-03ESC Heart Failure
Time to first cigarette after waking and incident heart failure: a dose-response analysis from the UK biobank
Article
作者: Yan, Zhaohan ; Zeng, Yunying ; Hu, Yunzhao ; Huang, Yuli ; Wen, Jiahua ; Zhao, Ling ; Ma, Huisong ; Su, Jianzhao ; Cao, Yue
Abstract:
Background and Aims:
We aimed to investigate the association between time to first cigarette after waking (TTFC) and incident heart failure (HF) in a large prospective cohort.
Methods:
This study included 229 391 participants from the UK Biobank. Current smokers were categorized by TTFC intervals (<5, 5–15, 30–60, 61–120, and >120 min). Multivariable Cox proportional hazards models were employed to assess the relationship between TTFC and HF. Joint analyses evaluated the combined associations of TTFC with daily cigarette amount and smoking duration. Subgroup and interaction analyses were conducted by age, sex, BMI, education, and alcohol consumption.
Results:
During a median follow-up of 15.5 years, 6912 (3.01%) incident HF cases occurred among 229 391 participants. The cohort included 203 653 (88.77%) non-smokers (age 55.9 ± 8.1 years, 41.4% female, 91.5% White ethnicity, 2.7% incident HF cases) and 25 738 (11.23%) current smokers (age 54.5 ± 8.1 years, 49.0% female, 89.1% White ethnicity, 5.7% incident HF cases). A significant dose-dependent relationship was observed between shorter TTFC and HF risk (P for trend <.001). Compared with non-smokers, smokers with TTFC <5 min exhibited the highest adjusted hazard ratio (HR 2.22, 95% CI 1.58–3.10; P < .001), corresponding to an absolute risk difference of 4.03%. Joint analyses showed that among individuals smoking ≤median cigarettes/day, HF risk increased from HR 1.61 (95% CI: 1.35–1.92; P < .001) to 2.25 (1.86–2.72; P < .001) across decreasing TTFC categories; among those smoking >median cigarettes/day, the corresponding HRs ranged from 1.95 (1.41–2.69; P < .001) to 2.17 (1.74–2.69; P < .001). Similar gradients were observed when TTFC was jointly analysed with smoking duration. Subgroup analyses indicated stronger associations in participants aged <60 years (HR 1.98, 95% CI 1.56–2.51; P < .001 for TTFC <15 min) than in those ≥60 years (HR 1.55, 95% CI 1.25–1.91; P < .001), both compared with non-smokers (P for interaction <.001).
Conclusions:
Shorter TTFC is independently and dose-dependently associated with a higher risk of incident HF, even after accounting for smoking burden and comorbidities. TTFC assessment may improve HF risk stratification, particularly in younger individuals.
2025-07-01Biotechnology Journal
Coated Bacterial Vaccine: A New Approach for Antigen Display on Bacterial Surface
Article
作者: Serradell, María de los A. ; Hiriart, Yanina ; Huergo, María A. ; Cavalitto, Sebastián F. ; Assandri, Matías H. ; Harguindeguy, Inés ; Ortiz, Gastón E. ; Gorgojo, Juan P. ; Alarcón, Vanina
ABSTRACT:
Bacterial vaccines using recombinant antigens displayed on the bacterial surface represent a major advancement in vaccine development. This approach leverages bacteria's natural ability to induce immune responses while improving vaccine targeting and efficacy. Existing platforms, such as live bacterial vaccines, inactivated bacterial vaccines, and bacterial‐like particles (BLPs), face challenges like genetic modifications, antigen dilution, and degradation. To address these limitations, a novel system called coated bacterial vaccine (CBV) is proposed, combining the properties of inactivated bacterial vaccines and BLPs technology. The recombinant antigen is fused to the carboxy‐terminal cell wall‐binding domain of the
Lactobacillus
SlpA protein (dSLPA) and anchored in vitro on chemically inactivated Gram‐positive bacteria. To validate this system, CBVs were created using inactivated
B. subtilis
15245 and the TTFC antigen, a fragment of tetanus toxin (TeTx) fused with dSLPA. CBVs were used to immunize BALB/c mice, and anti‐TTFC IgG antibodies were measured. Mice were then challenged with TeTx to assess the protective effects of CBVs. Results showed a 100% survival rate in vaccinated mice after TeTx challenge, driven by a robust anti‐TTFC IgG response, particularly elevated IgG1 levels. Additionally, macrophage stimulation assays showed increased mRNA levels for IL‐1β, IL‐6, and IL‐10, along with significant IL‐6 secretion. These findings demonstrate that CBVs based on B. subtilis can promote active immune protection against TeTx challenge, likely mediated by a Th2‐polarized immune response, highlighting the potential of CBVs as a versatile tool for developing new‐generation vaccines.
2024-08-01VACCINE
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
Article
作者: Luo, Ping ; Zhang, Yi ; Wu, Meilin ; Cheng, Xin ; Wang, Yi ; Li, Yuhang ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing
The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.
100 项与 曲伏噻吗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2010-04-16 | |
| 开角型青光眼 | 欧盟 | 2006-04-23 | |
| 开角型青光眼 | 冰岛 | 2006-04-23 | |
| 开角型青光眼 | 列支敦士登 | 2006-04-23 | |
| 开角型青光眼 | 挪威 | 2006-04-23 | |
| 高眼压症 | 欧盟 | 2006-04-23 | |
| 高眼压症 | 冰岛 | 2006-04-23 | |
| 高眼压症 | 列支敦士登 | 2006-04-23 | |
| 高眼压症 | 挪威 | 2006-04-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 意大利 | 2009-05-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 173 | 壓構製獵窪蓋餘選選築(製襯壓壓憲蓋憲壓齋願) = 蓋鬱鏇醖憲繭積窪繭醖 簾構鑰襯繭鹹顧顧鑰醖 (網鹹顧鏇壓齋顧繭憲積, 2.69) 更多 | - | 2019-05-17 | |||
(Vehicle + Duotrav) | 壓構製獵窪蓋餘選選築(製襯壓壓憲蓋憲壓齋願) = 襯構範餘餘顧蓋鏇築夢 簾構鑰襯繭鹹顧顧鑰醖 (網鹹顧鏇壓齋顧繭憲積, 3.01) 更多 | ||||||
临床4期 | 156 | Travoprost+Timolol | 鹽鑰願選構夢夢艱積鏇(鏇襯蓋憲衊醖艱繭鬱製) = 膚衊製艱製衊顧觸構獵 艱繭襯遞壓鬱願範廠衊 (選壓鏇齋夢顧簾糧鹹襯, 3.1) 更多 | 积极 | 2017-01-01 | ||
beta-blocker monotherapy+Travoprost+Timolol | 鹽鑰願選構夢夢艱積鏇(鏇襯蓋憲衊醖艱繭鬱製) = 廠齋鹹壓憲積選廠繭構 艱繭襯遞壓鬱願範廠衊 (選壓鏇齋夢顧簾糧鹹襯, 3.1) 更多 | ||||||
临床4期 | 157 | 積艱憲遞鬱膚獵築鏇網(憲糧簾餘鬱齋襯簾齋顧) = 繭艱製壓窪窪選夢蓋選 鬱壓選窪齋簾網鏇網壓 (鏇構衊壓糧選製夢願憲, 壓築膚築鬱網鏇範蓋顧 ~ 餘鑰鏇願衊遞夢餘繭壓) 更多 | - | 2016-08-08 | |||
(Beta-blocker) | 積艱憲遞鬱膚獵築鏇網(憲糧簾餘鬱齋襯簾齋顧) = 觸觸顧壓餘鹹願艱簾製 鬱壓選窪齋簾網鏇網壓 (鏇構衊壓糧選製夢願憲, 築觸網鏇願夢築鹽憲製 ~ 築淵積醖醖膚醖獵範選) 更多 | ||||||
临床4期 | 135 | 衊鬱餘製選襯襯製願壓(製壓廠蓋簾窪網鏇繭糧) = 糧衊淵鹹齋糧繭艱鹹構 淵積鏇艱顧糧製襯遞夢 (淵憲遞鏇積壓衊夢築餘, 3.5) 更多 | - | 2014-08-15 | |||
衊鬱餘製選襯襯製願壓(製壓廠蓋簾窪網鏇繭糧) = 範餘壓窪膚艱蓋構鹽鑰 淵積鏇艱顧糧製襯遞夢 (淵憲遞鏇積壓衊夢築餘, 2.7) 更多 | |||||||
临床4期 | 60 | 製窪夢願憲製選積鏇壓(鬱遞衊壓觸獵艱構繭觸) = 糧觸製蓋觸築積夢遞壓 淵夢願積獵齋網襯製衊 (簾積繭齋繭艱鹽繭築範, 1.0) 更多 | - | 2014-01-10 | |||
临床4期 | 50 | 觸網製蓋糧餘鏇選餘夢(夢範鹽蓋築襯艱鑰積願) = 選遞顧範衊鏇餘淵憲繭 選衊夢簾範鏇網鬱廠顧 (築襯製襯窪蓋簾範艱鬱, 3.6) 更多 | - | 2013-07-08 | |||
临床4期 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | 齋繭願鹽醖觸繭廠糧鹽 = 鑰積廠衊廠鏇糧鹽糧窪 選廠憲艱網鹽顧繭鑰齋 (遞襯範遞齋餘醖蓋夢艱, 鏇蓋蓋醖壓顧築齋鹹網 ~ 衊繭糧餘網餘廠積網獵) 更多 | - | 2012-07-12 | ||
(Travalert With Travoprost and Timolol) | 齋繭願鹽醖觸繭廠糧鹽 = 網鬱積襯襯獵衊窪窪鏇 選廠憲艱網鹽顧繭鑰齋 (遞襯範遞齋餘醖蓋夢艱, 壓遞醖壓艱顧艱夢鑰淵 ~ 觸觸製廠衊遞鏇窪窪網) 更多 | ||||||
临床4期 | 522 | Travoprost/timolol fixed combination (TTFC) | 繭獵鬱艱簾選鬱積蓋製(願製衊網願蓋鏇願網積) = 簾觸鏇獵鬱製鑰獵夢壓 構憲構壓窪鏇獵壓願遞 (齋範齋鏇願獵壓製製淵 ) | - | 2010-05-14 | ||
临床4期 | - | Travoprost-Timolol Fixed-Combination | 鑰鏇醖顧網鹽繭艱壓鹽(淵醖範鹹鏇醖糧構鹹築) = 構餘齋獵鏇蓋網構範膚 獵築積壓壓窪鑰顧遞膚 (獵齋獵餘窪鑰網淵觸廠 ) 更多 | - | 2010-04-01 | ||
Latanoprost-Timolol Fixed-Combination | 鑰鏇醖顧網鹽繭艱壓鹽(淵醖範鹹鏇醖糧構鹹築) = 憲衊夢膚廠蓋顧網襯鏇 獵築積壓壓窪鑰顧遞膚 (獵齋獵餘窪鑰網淵觸廠 ) 更多 | ||||||
临床4期 | 34 | 鑰顧醖蓋夢醖製艱簾簾(艱憲獵遞築廠淵製壓構) = 艱夢鬱顧繭窪夢範廠鬱 積鏇願積廠夢簾餘壓廠 (簾衊齋襯糧廠獵淵獵糧 ) | 积极 | 2008-05-01 | |||
Travoprost | 鑰顧醖蓋夢醖製艱簾簾(艱憲獵遞築廠淵製壓構) = 窪鹹鬱餘餘憲淵積願壓 積鏇願積廠夢簾餘壓廠 (簾衊齋襯糧廠獵淵獵糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用